Hypochondroplasia
Hypochondroplasia is a rare genetic disorder characterized by a form of dwarfism that results in shorter stature and skeletal abnormalities due to impaired bone growth.
Hypochondroplasia: Infigratinib for Growth
We are investigating whether infigratinib can help children aged 3 to 11 with hypochondroplasia grow taller and improve their overall health. The study will also look at the safety of this new treatment.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 5 and 11 years old?
- Are you currently pregnant or breastfeeding?
- Do you have a diagnosis of HCH (a condition causing short stature)?
- Are you taking any medications that could increase calcium or phosphorus levels in your blood?
- Have you had a fracture of a long bone or spine in the last 12 months?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Infigratinib
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Hopital Necker Enfants Malades
Service de médecine génomique des maladies rares
Montrouge, France
Haukeland University Hospital
Klinisk Forskningspost for Barn og unge
Bergen, Norway
Oslo University Hospital HF
Klinisk Forskningspost Barn
Oslo, Norway
Sponsor: Qed Therapeutics Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.